Literature DB >> 12667802

Analysis of the functional relationship between V3 loop and gp120 context with regard to human immunodeficiency virus coreceptor usage using naturally selected sequences and different viral backbones.

Patrizia Bagnarelli1, Lara Fiorelli, Manuela Vecchi, Alessia Monachetti, Stefano Menzo, Massimo Clementi.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) gp120 V3 loop plays a predominant role in chemokine receptor usage; however, other linear and nonlinear gp120 domains are involved in this step of the HIV-1 replication cycle. At present, the functional relationship between V3 and these domains with regard to coreceptor usage is unclear. To gain insights into the nature of this relationship in naturally selected viral variants, we developed a recombinant strategy based on two different gp120 backbones derived from CXCR4 (X4)- and CCR5 (R5)-tropic viral strains, respectively. Using this recombinant model system, we evaluated the phenotype patterns conferred to chimeric viruses by exogenous V3 loops from reference molecular clones and samples from infected subjects. In 13 of 17 recombinants (76%), a comparable phenotype was observed independently of the gp120 backbone, whereas in a minority of the recombinant viruses (4/17, 24%) viral infectivity depended on the gp120 context. No case of differential tropism using identical V3 sequence in the two gp120 contexts was observed. Site-directed mutagenesis experiments were performed to evaluate the phenotypic impact of specific V3 motifs. The data indicate that while the interaction of HIV-1 with chemokine receptors is driven by V3 loop and influenced by its evolutionary potential, the gp120 context plays a role in influencing the replication competence of the variants, suggesting that compensatory mutations occurring at sites other than V3 are necessary in some cases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667802     DOI: 10.1016/s0042-6822(02)00077-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  5 in total

1.  Gene silencing of HIV chemokine receptors using ribozymes and single-stranded antisense RNA.

Authors:  Amer Qureshi; Richard Zheng; Terry Parlett; Xiaoju Shi; Priyadhashini Balaraman; Sihem Cheloufi; Brendan Murphy; Christine Guntermann; Peter Eagles
Journal:  Biochem J       Date:  2006-03-01       Impact factor: 3.857

2.  High affinity CXCR4 inhibitors generated by linking low affinity peptides.

Authors:  Chaozai Zhang; Lina S Huang; Ruohan Zhu; Qian Meng; Siyu Zhu; Yan Xu; Huijun Zhang; Xiong Fang; Xingquan Zhang; Jiao Zhou; Robert T Schooley; Xiaohong Yang; Ziwei Huang; Jing An
Journal:  Eur J Med Chem       Date:  2019-04-01       Impact factor: 6.514

3.  Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1.

Authors:  Andrew Rosa Borges; Lindsay Wieczorek; Benitra Johnson; Alan J Benesi; Bruce K Brown; Richard D Kensinger; Fred C Krebs; Brian Wigdahl; Robert Blumenthal; Anu Puri; Francine E McCutchan; Deborah L Birx; Victoria R Polonis; Cara-Lynne Schengrund
Journal:  Virology       Date:  2010-09-28       Impact factor: 3.616

4.  Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients.

Authors:  Elisa Rita Ceresola; Silvia Nozza; Michela Sampaolo; Angela Rosa Pignataro; Diego Saita; Roberto Ferrarese; Marco Ripa; Wenjie Deng; James I Mullins; Enzo Boeri; Giuseppe Tambussi; Antonio Toniolo; Adriano Lazzarin; Massimo Clementi; Filippo Canducci
Journal:  J Antimicrob Chemother       Date:  2015-01-20       Impact factor: 5.790

5.  Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.

Authors:  Shawn E Kuhmann; Pavel Pugach; Kevin J Kunstman; Joann Taylor; Robyn L Stanfield; Amy Snyder; Julie M Strizki; Janice Riley; Bahige M Baroudy; Ian A Wilson; Bette T Korber; Steven M Wolinsky; John P Moore
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.